However, disturbances in the function and expression of glucose transporters may contribute to the pathophysiology observed in HD; these transporters, in particular GLUT1 and GLUT3, may be involved with targeted therapy in the treatment of HD. This evidence concerns the gene SLC2A3 and Huntington disease.